{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:18:06Z","timestamp":1783034286327,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Population-based organized prostate-specific antigen (PSA) screening is implemented in 80% of Japanese municipalities; however, Shiga Prefecture remains a unique exception without such a systematic program. This study characterized the longitudinal clinical features and treatment patterns in this opportunistic testing environment using data from 1716 patients diagnosed via prostate biopsy in 2012, 2017, and 2022. While median PSA levels remained stable (10.40\u201311.43 ng\/mL), median age at diagnosis increased from 72 to 74 years. Over the decade, the incidence of International Society of Urological Pathology Grade Group 1 and cT1c stages decreased significantly (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), with nearly 90% of cases being cT2 or higher in 2022. Risk classification showed a decrease in low-risk cases and a rise in high-risk cases. Regarding treatment, radical prostatectomy rates remained stable at approximately 25%, whereas the overall use of active surveillance (AS) increased from 1 to 9%. Notably, among low-risk patients, AS adoption rose markedly from 2.3% in 2012 to 68% in 2022. While clinical practices have evolved to successfully minimize unnecessary invasive intervention, these findings suggest that clinical progress alone cannot fully compensate for the lack of organized efforts to improve early detection.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-51230-6","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T11:23:41Z","timestamp":1777721021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate cancer detection in routine clinical practice: a large cohort study in Japan"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7924-9519","authenticated-orcid":false,"given":"Akinori","family":"Wada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Okinaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ishitoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Osafune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Jang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenkai","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Soga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Sakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Naya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Tsuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"51230_CR1","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","volume":"324","author":"WJ Catalona","year":"1991","unstructured":"Catalona, W. J. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl. J. Med. 324, 1156\u20131161 (1991).","journal-title":"N Engl. J. Med."},{"key":"51230_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/jnci\/djp001","volume":"101","author":"G Draisma","year":"2009","unstructured":"Draisma, G. et al. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J. Natl. Cancer Inst. 101, 374\u2013383 (2009).","journal-title":"J. Natl. Cancer Inst."},{"key":"51230_CR3","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der, F. H. et al. Screening and prostate\u2013cancer mortality in a randomized European study. N Engl. J. Med. 360, 1320\u20131328 (2009).","journal-title":"N Engl. J. Med."},{"key":"51230_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson, J. et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur. Urol. 76, 43\u201351 (2019).","journal-title":"Eur. Urol."},{"key":"51230_CR5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","volume":"360","author":"GL Andriole","year":"2009","unstructured":"Andriole, G. L. et al. Mortality results from a randomized prostate\u2013cancer screening trial. N Engl. J. Med. 360, 1310\u20131319 (2009).","journal-title":"N Engl. J. Med."},{"key":"51230_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bju.14580","volume":"123","author":"PF Pinsky","year":"2019","unstructured":"Pinsky, P. F. et al. Extended follow-up for prostate cancer incidence and mortality among participants in the prostate, lung, colorectal and ovarian randomized cancer screening trial. BJU Int. 123, 854\u2013860 (2019).","journal-title":"BJU Int."},{"key":"51230_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","volume":"319","author":"RM Martin","year":"2018","unstructured":"Martin, R. M. et al. Effect of a Low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial. JAMA 319, 883\u2013895 (2018).","journal-title":"JAMA"},{"key":"51230_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1740774510374091","volume":"7","author":"PF Pinsky","year":"2010","unstructured":"Pinsky, P. F. et al. Assessing contamination and compliance in the prostate component of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Clin. Trials. 7, 303\u2013311 (2010).","journal-title":"Clin. Trials"},{"key":"51230_CR9","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJMc1515131","volume":"374","author":"JE Shoag","year":"2016","unstructured":"Shoag, J. E., Mittal, S. & Hu, J. C. Reevaluating PSA testing rates in the PLCO Trial. N Engl. J. Med. 374, 1795\u20131796 (2016).","journal-title":"N Engl. J. Med."},{"key":"51230_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMc1607379","volume":"375","author":"P Pinsky","year":"2016","unstructured":"Pinsky, P. & Prorok, P. More on Reevaluating PSA testing rates in the PLCO Trial. N Engl. J. Med. 375, 1500\u20131501 (2016).","journal-title":"N Engl. J. Med."},{"key":"51230_CR11","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2024.4011","volume":"331","author":"RM Martin","year":"2024","unstructured":"Martin, R. M. et al. Prostate-specific antigen screening and 15-year prostate cancer mortality: A secondary analysis of the CAP randomized clinical trial. JAMA 331, 1460\u20131470 (2024).","journal-title":"JAMA"},{"key":"51230_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","volume":"84","author":"II de Vos","year":"2023","unstructured":"de Vos, I. I. et al. A detailed evaluation of the effect of prostate-specific antigen-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam section of the European randomised study of screening for prostate cancer. Eur. Urol. 84, 426\u2013434 (2023).","journal-title":"Eur. Urol."},{"key":"51230_CR13","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic, D. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: A systematic review and meta-analysis. BMJ 362, k3519. https:\/\/doi.org\/10.1136\/bmj.k3519 (2018).","journal-title":"BMJ"},{"key":"51230_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.euo.2023.08.011","volume":"7","author":"R Hogenhout","year":"2024","unstructured":"Hogenhout, R., Remmers, S., van Slooten-Midderigh, M. E., de Vos, I. I. & Roobol, M. J. ERSPC rotterdam study group from screening to mortality reduction: An overview of empirical data on the patient journey in European randomized study of screening for prostate cancer Rotterdam after 21 years of follow-up and a reflection on quality of life. Eur. Urol. Oncol. 7, 713\u2013720 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"51230_CR15","doi-asserted-by":"publisher","first-page":"e077738","DOI":"10.1136\/bmj-2023-077738","volume":"4","author":"S Vaccarella","year":"2024","unstructured":"Vaccarella, S. et al. Prostate cancer incidence and mortality in Europe and implications for screening activities: Population based study. BMJ 4, 386:e077738. https:\/\/doi.org\/10.1136\/bmj-2023-077738 (2024).","journal-title":"BMJ"},{"key":"51230_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86, 148\u2013163 (2024).","journal-title":"Eur. Urol."},{"key":"51230_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei, J. T. et al. Early detection of prostate cancer: AUA\/SUO guideline part I: Prostate cancer screening. J. Urol. 210, 46\u201353 (2023).","journal-title":"J. Urol."},{"key":"51230_CR18","unstructured":"Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Cancer Screening Performance Measures Data Book)."},{"key":"51230_CR19","unstructured":"Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare)."},{"key":"51230_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/mco.2022.2599","volume":"18","author":"S Kageyama","year":"2022","unstructured":"Kageyama, S. et al. Population\u2013based prostate\u2013specific antigen screening for prostate cancer may have an indirect effect on early detection through opportunistic testing in Kusatsu City, Shiga, Japan. Mol. Clin. Oncol. 18, 3. https:\/\/doi.org\/10.3892\/mco.2022.2599 (2022).","journal-title":"Mol. Clin. Oncol."},{"key":"51230_CR21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/pros.24212","volume":"81","author":"Y Okinaka","year":"2021","unstructured":"Okinaka, Y. et al. Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan. Prostate 81, 1172\u20131178 (2021).","journal-title":"Prostate"},{"key":"51230_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1464-410X.2012.11611.x","volume":"111","author":"PM Pierorazio","year":"2013","unstructured":"Pierorazio, P. M., Walsh, P. C., Partin, A. W. & Epstein, J. I. Prognostic Gleason grade grouping: Data based on the modified Gleason scoring system. BJU Int. 111, 753\u2013760 (2013).","journal-title":"BJU Int."},{"key":"51230_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","volume":"68","author":"GR Arnsrud","year":"2015","unstructured":"Arnsrud, G. R., Holmberg, E., Lilja, H., Stranne, J. & Hugosson, J. Opportunistic testing organized prostate-specific antigen screening: Outcome after 18 years in versus the G\u00f6teborg randomized population-based prostate cancer screening trial. Eur. Urol. 68, 354\u2013360 (2015).","journal-title":"Eur. Urol."},{"key":"51230_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot, M. et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl. J. Med. 382, 917\u2013928 (2020).","journal-title":"N Engl. J. Med."},{"key":"51230_CR25","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl. J. Med. 378, 1767\u20131777 (2018).","journal-title":"N Engl. J. Med."},{"key":"51230_CR26","unstructured":"Shiga Prefectural Government. Cancer Registry. (2025). https:\/\/www.pref.shiga.lg.jp\/ippan\/kenkouiryouhukushi\/iryo\/15264.html. Accessed April 18."},{"key":"51230_CR27","first-page":"859","volume":"13","author":"T Saito","year":"2021","unstructured":"Saito, T. et al. Significance of PSA screening in Niigata, Japan: Survey of actual status of new cases of prostate cancer. Res. Rep. Urol. 13, 859\u2013866 (2021).","journal-title":"Res. Rep. Urol."},{"issue":"11","key":"51230_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/pros.23997","volume":"80","author":"T Tabei","year":"2020","unstructured":"Tabei, T. et al. Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening. Prostate 80 (11), 824\u2013830 (2020).","journal-title":"Prostate"},{"key":"51230_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1442-2042.2007.01957.x","volume":"15","author":"K Okihara","year":"2008","unstructured":"Okihara, K. et al. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan. Int. J. Urol. 15, 156\u2013160 (2008).","journal-title":"Int. J. Urol."},{"key":"51230_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/bju.15980","volume":"131","author":"G Wei","year":"2023","unstructured":"Wei, G. et al. Decade-long trends in prostate cancer biopsy grade groups and treatment within a population-based registry. BJU Int. 131, 36\u201342 (2023).","journal-title":"BJU Int."},{"key":"51230_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bju.13676","volume":"120","author":"S Loeb","year":"2017","unstructured":"Loeb, S. et al. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int. 120, 61\u201368 (2017).","journal-title":"BJU Int."},{"key":"51230_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/pros.24894","volume":"85","author":"Y Miura","year":"2025","unstructured":"Miura, Y. et al. Analytical and real-world clinical characterization of S2,3PSA% test in MRI fusion targeted prostate biopsy population. Prostate 85, 869\u2013887 (2025).","journal-title":"Prostate"},{"key":"51230_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s10147-016-1049-y","volume":"22","author":"S Hatakeyama","year":"2017","unstructured":"Hatakeyama, S., Yoneyama, T., Tobisawa, Y. & Ohyama, C. Recent progress and perspectives on prostate cancer biomarkers. Int. J. Clin. Oncol. 22, 214\u2013221 (2017).","journal-title":"Int. J. Clin. Oncol."},{"key":"51230_CR34","doi-asserted-by":"crossref","unstructured":"Cooperberg, M. R. et al. Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US. JAMA Netw .Open. 6(3), e231439 (2023).","DOI":"10.1001\/jamanetworkopen.2023.1439"},{"key":"51230_CR35","doi-asserted-by":"crossref","unstructured":"Kawai, T. et al. ; Japan Study Group of Prostate Cancer (J-CaP). Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: A nationwide multi-institutional study. Jpn. J. Clin. Oncol. 54(9), 1045\u20131051 (2024).","DOI":"10.1093\/jjco\/hyae079"},{"key":"51230_CR36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1615869","volume":"377","author":"TJ Wilt","year":"2017","unstructured":"Wilt, T. J. et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl. J. Med. 377, 132\u2013142 (2017).","journal-title":"N Engl. J. Med."},{"key":"51230_CR37","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy, F. C. et al. 10-Year Outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl. J. Med. 375, 1415\u20131424 (2016).","journal-title":"N Engl. J. Med."},{"key":"51230_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/bju.16727","volume":"136","author":"II de Vos","year":"2025","unstructured":"de Vos, I. I. et al. Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment. BJU Int. 136, 245\u2013253 (2025).","journal-title":"BJU Int."},{"issue":"18","key":"51230_CR39","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"8","author":"D Grossman","year":"2018","unstructured":"US Preventive Services Task Force & Grossman, D. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA 8 (18), 1901\u20131913 (2018).","journal-title":"JAMA"},{"key":"51230_CR40","doi-asserted-by":"publisher","first-page":"r1179","DOI":"10.1136\/bmj.r1179","volume":"10","author":"A Lucassen","year":"2025","unstructured":"Lucassen, A., McCartney, M. & Sullivan, R. Prostate cancer: Polygenic risk scores have not shown clinical benefit. BMJ 10, 389:r1179 (2025).","journal-title":"BMJ"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51230-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:37:08Z","timestamp":1783031828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51230-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51230"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51230-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Shiga University of Medical Science (Approval number: R2023-046).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained in the form of Opt-out on the web site of Shiga University of Medical Science Hospital and each study center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"20379"}}